智翔金泰前三季度净利亏损3.33亿元，同比减亏

Core Viewpoint - Zhixiang Jintai (688443) reported a significant increase in revenue for the first three quarters of 2025, with a total revenue of 208 million yuan, reflecting a year-on-year increase of 1562.05%. However, the company recorded a net profit loss of 333 million yuan, indicating a reduction in losses compared to the previous year [1]. Financial Performance - The company's revenue for the first three quarters reached 208 million yuan, marking a substantial increase of 1562.05% year-on-year [1]. - The net profit attributable to shareholders was -333 million yuan, showing a reduction in losses compared to the same period last year [1]. Revenue Drivers - The increase in revenue was attributed to the recognition of licensing income from the GR1803 injection authorization and commercialization agreement, as well as sales growth from the company's first commercial product, the Selqi monoclonal antibody injection (Jinlixi) [1]. - The absence of share-based payment expenses in the reporting period, due to the completion of the company's 2022 equity incentive plan service period, also contributed to the narrowing of net losses [1].